Literature DB >> 26855691

Inflammasome activation in decompensated liver cirrhosis.

José M González-Navajas1.   

Abstract

Inflammation participates in the pathogenesis of many liver diseases, including liver cirrhosis. Certain inflammatory citokines, such as interleukin (IL)-1β and IL-18, are produced after the activation of a multiprotein complex known as the inflammasome. Activation of the inflammasome has been documented in several liver diseases, but its role in the development and progression of liver cirrhosis or the complications associated with this disease is still largely unknown. We have recently studied the impact of the inflammasome in the sterile inflammatory response that takes place in the ascitic fluid of patients with decompensated cirrhosis, providing evidence that activation of the absent in melanoma 2 (AIM2) inflammasome is an important response in these patients. Ascitic fluid-derived macrophages were able to mount a very robust AIM2-mediated response even in the absence of a priming signal, which is usually required for the full activation of all the inflammasomes. In addition, high level of inflammasome activation in these patients was associated with a higher degree of liver disease and an increased incidence of spontaneous bacterial peritonitis. These results may help explain the exacerbated inflammatory response that usually occurs in patients with decompensated cirrhosis in the absence of detectable infections. Thus, inflammasomes should be considered as possible therapeutic targets in sterile inflammatory complications in patients with cirrhosis.

Entities:  

Keywords:  Absent in melanoma 2; Ascites; Cirrhosis; Inflammasome; Interleukin-1β

Year:  2016        PMID: 26855691      PMCID: PMC4733463          DOI: 10.4254/wjh.v8.i4.207

Source DB:  PubMed          Journal:  World J Hepatol


  19 in total

Review 1.  Inflammasomes in health and disease.

Authors:  Till Strowig; Jorge Henao-Mejia; Eran Elinav; Richard Flavell
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

Review 2.  The inflammasomes.

Authors:  Kate Schroder; Jurg Tschopp
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 3.  Regulation of inflammasome signaling.

Authors:  Vijay A K Rathinam; Sivapriya Kailasan Vanaja; Katherine A Fitzgerald
Journal:  Nat Immunol       Date:  2012-03-19       Impact factor: 25.606

4.  Bacterial translocation of enteric organisms in patients with cirrhosis.

Authors:  I Cirera; T M Bauer; M Navasa; J Vila; L Grande; P Taurá; J Fuster; J C García-Valdecasas; A Lacy; M J Suárez; A Rimola; J Rodés
Journal:  J Hepatol       Date:  2001-01       Impact factor: 25.083

Review 5.  Inflammasomes in liver diseases.

Authors:  Gyongyi Szabo; Timea Csak
Journal:  J Hepatol       Date:  2012-05-23       Impact factor: 25.083

6.  Hepatitis C virus activates interleukin-1β via caspase-1-inflammasome complex.

Authors:  Dylan Burdette; Adam Haskett; Lance Presser; Steven McRae; Jawed Iqbal; Gulam Waris
Journal:  J Gen Virol       Date:  2011-10-12       Impact factor: 3.891

7.  Asc and Ipaf Inflammasomes direct distinct pathways for caspase-1 activation in response to Legionella pneumophila.

Authors:  Christopher L Case; Sunny Shin; Craig R Roy
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

Review 8.  Inflammasome and IL-1beta-mediated disorders.

Authors:  Hal M Hoffman; Alan A Wanderer
Journal:  Curr Allergy Asthma Rep       Date:  2010-07       Impact factor: 4.806

9.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

10.  AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC.

Authors:  Veit Hornung; Andrea Ablasser; Marie Charrel-Dennis; Franz Bauernfeind; Gabor Horvath; Daniel R Caffrey; Eicke Latz; Katherine A Fitzgerald
Journal:  Nature       Date:  2009-01-21       Impact factor: 49.962

View more
  5 in total

1.  NLRP3 inflammasome activation results in liver inflammation and fibrosis in mice infected with Schistosoma japonicum in a Syk-dependent manner.

Authors:  Ya-Qi Lu; Shan Zhong; Nan Meng; Yin-Ping Fan; Wang-Xian Tang
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

Review 2.  Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step.

Authors:  Hiroshi Fukui
Journal:  J Clin Transl Hepatol       Date:  2017-06-29

3.  Bloodstream infection due to Escherichia coli in liver cirrhosis patients: clinical features and outcomes.

Authors:  Bo Tu; Jingfeng Bi; Dan Wu; Peng Zhao; Lei Shi; Yangxin Xie; Xin Zhang; Zhe Xu; Suxia Liu; Xinhua Wang; Xiaoxi Li; Fusheng Wang; Enqiang Qin
Journal:  Oncotarget       Date:  2017-12-13

4.  Prognostic value of neutrophil-to-lymphocyte ratio in cirrhotic patients with acute-on-chronic liver failure.

Authors:  Stefan Chiriac; Carol Stanciu; Ana Maria Singeap; Catalin Victor Sfarti; Tudor Cuciureanu; Anca Trifan
Journal:  Turk J Gastroenterol       Date:  2020-12       Impact factor: 1.852

5.  Melatonin prevents oxidative stress, inflammatory activity, and DNA damage in cirrhotic rats.

Authors:  Josieli R Colares; Renata M Hartmann; Elizângela G Schemitt; Sandielly R B Fonseca; Marilda S Brasil; Jaqueline N Picada; Alexandre S Dias; Aline F Bueno; Cláudio A Marroni; Norma P Marroni
Journal:  World J Gastroenterol       Date:  2022-01-21       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.